Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
- Investor focus: cash position, R&D spending and pipeline updates in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net product revenue $17.8M, AVLAYAH’s second full commercial quarter, with Q4 guidance of $30.0M-$32.0M
- U.S. commercial coverage exceeded 70%, up from more than 50%, with 20 state Medicaid programs covering AVLAYAH
- Net income $70.1M included a one-time $194.0M gain from selling a Priority Review Voucher, limiting earnings quality
- Cash, cash equivalents and marketable securities reached approximately $1.0B, strengthening funding for pipeline development
- Zafinofusp alfa BLA submission remains on track for 2027, while five TransportVehicle programs are expected to produce data in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.